All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are now available for routine office visits. VCS is keeping updated on current state and local guidance for the Covid vaccine rollout plan – until then please be advised our office will not write letters of recommendation or advise patients until the state and federal guidelines are published. FOR THE LATEST UP TO DATE INFORMATION, ALERTS, VACCINE INFORMATION AND CANCELLATIONS PLEASE CLICK HERE

Clinical Trial: 20189

Trial Status: Open
Disease Type: Esophageal/Gastric
Trial ID 20189
Sponsor ID Incyte/ IQVIA

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Principal Investigator
Ajay Dar, MD

Locations

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID US-60010-001 NAPOLI3
Sponsor ID US-60010-001 NAPOLI3

An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic

Principal Investigator
Keeran R. Sampat, MD
Trial ID 8951-CL-0103
Sponsor ID 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Principal Investigator
Timothy A. McCarthy, MD